TEA Comparison: What Do the Studies Actually Say?

Systematic breakdown of published cultivated meat cost analyses

Work in Progress — Feedback Welcome

This comparison is largely AI-generated based on our reading of the cited sources. We are not the domain experts — this is a framework for structured discussion, not a definitive assessment. We welcome corrections and additional data points via Hypothesis annotations (click the < tab on the right) or at our upcoming workshop. All contributions will be acknowledged.

Return to: Interactive Cost Model | Background: How Cultured Chicken is Made | Technical details: Documentation | Workshop (Apr 2026)

Why Comparison Is Hard

Cultivated meat cost estimates from different studies are often not directly comparable. They differ in:

  • Species: Chicken (Pasitka 2024) vs. generic mammalian/CHO-like cells (Humbird 2021) vs. unspecified (CE Delft 2021)
  • Output basis: Pure wet cell mass vs. cultivated ingredient vs. hybrid product vs. retail-equivalent — see definitions in our explainer
  • Scale assumptions: 2m³ reactors (Pasitka) vs. 50m³ (Humbird sensitivity) vs. future industrial scenarios (CE Delft)
  • Media assumptions: Hydrolysate-based vs. pharma-grade vs. animal-component-free
  • Time horizon: Current technology vs. 2030 projections vs. steady-state

The tables below attempt to put these studies on a comparable footing. Where a direct comparison isn’t possible, we note the gap.

Presentation 1: Study Overview

Study Species / Output Basis Headline Figures Scale / Process Key Context
Pasitka et al. 2024 (Nature Food + supplement) Chicken; pure cell mass (ACF medium) $13.75/kg (large perfusion), $15.03/kg (TFF), $22.27/kg (ATF) — Supplement Table S10. The widely-cited ~$6/lb figure is a 50/50 hybrid product (per GFI State of Industry 2024); pure cell mass costs are higher. 2×25m³ (perfusion), 10×5m³ (TFF), 25×2m³ (ATF); 14.6% annual capital charge Believer Meats shut down Dec 2025. Only chicken-specific TEA in the literature.
Humbird 2021 (Open Philanthropy) Generic mammalian (CHO-like); wet cell mass $37/kg (fed-batch), $51/kg (perfusion), ~$22/kg (with hydrolysates), ~$16/kg (asymptotic extreme scale) Fed-batch ~110 g/L; perfusion up to 195 g/L in 2m³; sensitivity to 50m³ Not chicken-specific; amino acid costs likely overestimated 2-10× per GFI 2025
CE Delft 2021 (corrigendum) Non-specific CM slurry/paste (~70-77% water) $6.43/kg (best-case) to ~$25/kg (mid-scenarios) Future 2030-style industrial scenarios; one scenario removed as physically inconsistent Not species-specific; product is undefined slurry; best-case combines multiple optimistic assumptions
GFI component reports (2020-2025) Component studies, not full TEAs Amino acids: $0.02-$0.17/L, could fall below $5/kg CM (2025 report). Growth factors: competitive target ~$1/kg CM with 8-13 L/kg media use (GF analysis). Scale-up trends: media recycling increasingly common; 316L stainless ~40% more expensive than 304 (2024 survey). Based on supplier quotes, industry surveys, and techno-economic modeling Not full TEAs; use to update individual parameter priors rather than total cost estimates
Goodwin et al. 2024 (Nature Food) Scoping review — no cost estimate — Reviews methodology of published TEAs Finds many TEAs rely on assumptions inconsistent with CM bench literature

Presentation 2: Component-by-Component Breakdown

This is where the differences become clearest. Each study makes different assumptions about the key cost drivers.

Media & Amino Acid Costs

Parameter Pasitka 2024 Humbird 2021 CE Delft 2021 GFI 2025 (amino acids only)
Media type Animal-component-free (ACF), hydrolysate-based Pharma-grade baseline; hydrolysate sensitivity Varies by scenario N/A (component study)
Media cost ($/L) $0.63/L (reported) $1-4/L (pharma); ~$0.50-1.50/L (hydrolysate) Varies; not always explicit Amino acid contribution only: $0.02-$0.17/L
Amino acid source Plant hydrolysates Purified amino acids (baseline); soy hydrolysate (sensitivity) Varies Supplier-quoted prices for purified AAs
Hydrolysate assumption Validated in lab at scale “Requires further study” for suitability Scenario-dependent Notes deficiencies in key AAs; supplementation needed

Growth Factors

Parameter Pasitka 2024 Humbird 2021 CE Delft 2021
GF approach ACF medium (proprietary formulation) Recombinant FGF-2 + TGF-β at bulk pricing Scenario-dependent
GF cost contribution Included in $0.63/L media cost (not separately reported) $3-4/kg at 100 kTA (assumes bulk pricing breakthroughs) Not separately broken out in most scenarios
Key assumption Proprietary low-cost formulation achieved Bulk pricing at $4/g FGF-2 (vs. ~$50,000/g current research) Varies

Cell Density & Process Mode

Parameter Pasitka 2024 Humbird 2021 CE Delft 2021
Achieved density 130×10⁶ cells/mL (~43% w/v) Fed-batch: ~110 g/L; Perfusion: up to 195 g/L Varies (10-100+ g/L across scenarios)
Process mode Continuous perfusion Fed-batch (primary); perfusion (sensitivity) Multiple scenarios
Media turnover Continuous (high turnover) Fed-batch: ~1×; Perfusion: higher Varies

Capital Costs & Financing

Parameter Pasitka 2024 Humbird 2021 CE Delft 2021
Reactor type Modeled: 2m³ (ATF), 5m³ (TFF), 25m³ (perfusion) 2m³ (perfusion), up to 50m³ (fed-batch sensitivity) Large STRs (future scenarios)
Equipment grade Not specified (modeled cost) Pharma-grade 316L stainless steel Varies; includes food-grade scenarios
Annual capital charge 14.6% ~20% (high-risk early stage) Varies by scenario; notes lower ROI requirements needed
WACC / financing Implicit in 14.6% charge High (early-stage biotech) Explicitly notes cost reduction requires lower-than-standard ROI

Scale

Parameter Pasitka 2024 Humbird 2021 CE Delft 2021
Plant capacity 50,000 L working volume ~20 kTA reference; sensitivity to larger Future industrial (>10 kTA)
Utilization Continuous operation assumed 90% utilization Varies

Presentation 3: Cost Waterfall Comparison

Pasitka 2024
(Chicken, large perfusion)

Media
~$6-8/kg
Growth factors
incl.
CAPEX
~$3-4/kg
Fixed OPEX
~$2/kg
$13.75/kg
Pure cell mass, ACF medium
Believer Meats (shut down Dec 2025)

Humbird 2021
(Generic mammalian, fed-batch)

Media
~$19/kg (AAs)
Growth factors
~$3/kg
CAPEX
~$12/kg
Fixed OPEX
~$3/kg
$37/kg
Wet cell mass, pharma-grade inputs
Not chicken-specific

Humbird 2021
(With hydrolysates)

Media
~$3/kg
Growth factors
~$3/kg
CAPEX
~$12/kg
Fixed OPEX
~$3/kg
~$22/kg
Wet cell mass, hydrolysate scenario
Hydrolysate suitability "requires further study"

Note: Growth factor costs in Pasitka are included in the media cost figure ($0.63/L ACF medium) and not separately broken out. Humbird reports GFs at $3-4/kg assuming bulk pricing breakthroughs. Component breakdown for CE Delft is omitted as they do not report comparable per-kg component costs across most scenarios.

Presentation 4: Key Assumption Divergences

Rather than showing all numbers, this highlights where the studies most disagree — the parameters where your prior most affects your conclusion.

Parameter Divergence Optimistic end Pessimistic end Why it matters
Amino acid / media cost HIGH $0.63/L (Pasitka ACF medium) — with GFs included $1-4/L (Humbird pharma-grade) — excluding GFs GFI 2025 suggests Humbird's AA prices were 2-10× too high. But Pasitka's $0.63/L includes proprietary GF formulation — not apples-to-apples.
Growth factor cost HIGH Included in $0.63/L (Pasitka); ~$0/kg if autocrine lines work $3-4/kg (Humbird, assumes bulk breakthroughs); potentially $100+/kg without breakthroughs The single most pivotal uncertainty. Multiple breakthrough technologies in development but none proven at commercial scale.
Output basis HIGH 50/50 hybrid (~$6/lb headline) or pure cell mass ($13.75/kg) Pure wet cell mass ($37-51/kg, Humbird) Comparing hybrid product cost to pure cell mass cost is an apples-to-oranges error that inflates apparent agreement between studies.
Cell density MEDIUM 130×10⁶ cells/mL / ~43% w/v (Pasitka, demonstrated) 110 g/L fed-batch / 195 g/L perfusion limit (Humbird, modeled) Higher density = less media per kg. Studies roughly agree on achievable ranges but differ on whether high density comes with offsetting costs (filters, contamination).
Species MEDIUM Chicken cells (Pasitka — spontaneous immortalization, robust growth) Generic mammalian / CHO-like (Humbird — conservative, well-characterized) Chicken cells may have genuine biological advantages (immortalization without genetic modification), but most TEAs don't use chicken-specific parameters.
Capital charge / WACC MEDIUM 14.6% annual (Pasitka) ~20%+ (Humbird, early-stage risk); CE Delft notes lower ROI needed for cost targets Financing cost reflects perceived industry risk. Mature food = 8-12%; early biotech = 15-25%.
Reactor scale LOW 25m³ (Pasitka large perfusion); larger in CE Delft futures 2m³ (Pasitka ATF, Humbird perfusion); 50m³ (Humbird sensitivity) Reactor size affects CAPEX/kg through economies of scale but is less pivotal than media/GF costs.

Cautious Synthesis

The synthesis below is not a conclusion we are confident in or standing behind. It is a largely AI-generated interpretation of the evidence we are currently examining. We do not want to prejudge the questions our workshop is designed to explore, and we are not the domain experts. This is presented as a starting point for structured discussion. Please push back on it.

Based on the studies above, here is a rough bracketing for pure cultivated chicken cell mass cost in a steady-state scenario (~2036):

Band Range ($/kg) Basis
Optimistic ~$14-18/kg Anchored by Pasitka supplement's chicken-specific large-scale perfusion ($13.75/kg) and TFF ($15.03/kg). Modeled, not demonstrated at commercial scale. Believer Meats' shutdown adds uncertainty about near-term achievability.
Central ~$18-35/kg Bracketing chicken-specific Pasitka against Humbird's more pessimistic generic TEA, adjusted for GFI 2025 evidence that Humbird's amino acid costs were substantially overestimated.
Pessimistic >$35-60+/kg Humbird-style outcomes ($37-51/kg) if food-grade media, hydrolysate, and growth factor improvements are slower than projected.

Key reasons the optimistic end may be too low: the Pasitka results come from a company that subsequently shut down; the widely-cited $6/lb headline is a hybrid product figure; and hydrolysate performance at commercial scale is still unproven.

Key reasons the pessimistic end may be too high: GFI 2025 evidence materially weakens Humbird’s amino acid cost assumptions; chicken cells may have genuine advantages over the generic mammalian model Humbird uses; and multiple growth factor cost-reduction approaches are in active development.

If the pure cell mass costs above are correct, hybrid products could be cheaper:

  • At 50% CM inclusion: ~$7-18/kg blended cost (with plant filler at ~$3/kg)
  • At 25% CM inclusion: ~$5-12/kg blended cost
  • At 3% CM inclusion (like GOOD Meat’s retail product): close to plant-based cost

The “right” CM inclusion rate for a marketable product is itself uncertain and depends on consumer acceptance, regulatory requirements, and what functionality the cultivated cells provide (taste, texture, nutrition). GFI notes more research is needed to identify optimal ratios.

How Our Dashboard Relates to These Studies

Our interactive cost model is not a replication of any single study. It is a Monte Carlo framework that lets you explore the parameter space these studies occupy. Some key relationships:

  • Default parameter ranges are informed by Humbird 2021 (pessimistic baseline) and GFI component reports (media cost revision), with Pasitka 2024 providing chicken-specific anchoring
  • The hydrolysate toggle (75% base probability) explores the Humbird pharma-grade → hydrolysate cost shift
  • The growth factor toggle (50% base probability) captures the binary uncertainty about breakthrough technologies
  • The maturity slider creates correlated “good world” / “bad world” scenarios similar to the spread between optimistic and pessimistic TEAs

A planned future enhancement is “reproduce a paper” preset buttons that lock parameters to match specific published TEA assumptions (Humbird, CE Delft, Pasitka). This would make it easier to see exactly which parameter differences drive the cost gap between studies.

This page is part of The Unjournal’s Pivotal Questions initiative. Feedback via Hypothesis, GitHub issues, or at our workshop.